A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
← catalyst calendarNCT05137054 · readout in 584 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
317estimated
Sites
42
Countries
France, Greece, Israel +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-17 | actual | When the study began enrolling |
| Primary completion | 2028-03-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-03-24 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Linvoseltamab — also filed as REGN5458, Lynozyfic™
- Drug: Daratumumab — also filed as Darzalex®; Darzalex Faspro™
- Drug: Carfilzomib — also filed as Kyprolis®
- Drug: Lenalidomide — also filed as Revlimid®
- Drug: Bortezomib — also filed as Velcade®
- Drug: Pomalidomide — also filed as Imnovid, Pomalyst®
- Drug: Isatuximab — also filed as Sarclisa®
- Drug: Fianlimab — also filed as REGN3767
- Drug: Cemiplimab — also filed as LIBTAYO, REGN2810
- Drug: Nirogacestat — also filed as PF-03084014
- Drug: Cevostamab — also filed as BFCR4350A, RO7187797
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
measured Up to 28 Days
Incidence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to 5 Years
Severity of TEAEs
measured Up to 5 Years
Incidence of Serious Adverse Events (SAEs)
measured Up to 5 Years
Severity of SAEs
measured Up to 5 Years
Incidence of Adverse Events of Special Interest (AESIs)
measured Up to 5 Years
Severity of AESIs
measured Up to 5 Years
Incidence of laboratory abnormalities
measured Up to 5 Years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed